Comparison of RNA‐ and DNA‐based methods for measurable residual disease analysis in NPM1 ‐mutated acute myeloid leukemia-Reference-Cited by-同舟云学术

Comparison of RNA‐ and DNA‐based methods for measurable residual disease analysis in NPM1 ‐mutated acute myeloid leukemia

Published:2021-05-30 Issue:4 Volume:43 Page:664-674
ISSN:1751-5521
Container-title:International Journal of Laboratory Hematology
language:en
Short-container-title:Int J Lab Hematology

Author:

Pettersson Louise¹²^ORCID,Johansson Alm Sofie³,Almstedt Alvar⁴,Chen Yilun⁵,Orrsjö Gustav⁶,Shah‐Barkhordar Giti⁷,Zhou Li⁸,Kotarsky Heike⁸,Vidovic Karina¹,Asp Julia³⁹,Lazarevic Vladimir¹⁰^ORCID,Saal Lao H.⁵¹¹,Fogelstrand Linda³⁹^ORCID,Ehinger Mats¹⁸

Affiliation:

1. Department of Clinical Sciences Division of Pathology Lund University Skane University Hospital Lund Sweden

2. Department of Pathology Halland Hospital Halmstad, Region Halland Halmstad Sweden

3. Department of Laboratory Medicine Institute of Biomedicine Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden

4. SciLife Clinical Genomics Gothenburg Gothenburg Sweden

5. Department of Clinical Sciences Division of Oncology Faculty of Medicine Lund University Lund Sweden

6. Section for Hematology and Coagulation Sahlgrenska University Hospital Gothenburg Sweden

7. Department of Clinical Genetics and Genomics Sahlgrenska University Hospital Gothenburg Sweden

8. Klinisk Patologi Region Laboratories Region Skåne Lund Sweden

9. Department of Clinical Chemistry Sahlgrenska University Hospital Gothenburg Sweden

10. Department of Hematology, Oncology and Radiation Physics Lund University Skane University Hospital Lund Sweden

11. Lund University Cancer Center Medicon Village Lund Sweden

Funder

Cancerfonden

Vetenskapsrådet

Publisher

Wiley

Subject

Biochemistry (medical),Clinical Biochemistry,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.13608

Reference42 articles.

1. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

2. Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives

3. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)

4. Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ancillary Tests;Pediatric Pathology of Hematopoietic and Histiocytic Disorders;2024-02-15

2. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation;Journal of Clinical Oncology;2024-01-17

3. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real‐time PCR to digital droplet PCR;Pediatric Transplantation;2023-02-07

4. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation;International Journal of Molecular Sciences;2023-02-05

5. Normalization of NPM1 mutant transcript to the wild‐type transcript;eJHaem;2022-09-27